Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 3
2011 8
2012 4
2013 5
2014 3
2015 1
2017 2
2018 3
2019 3
2020 7
2021 4
2022 5
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M. Shiota M, et al. Among authors: tatarano s. Endocr Relat Cancer. 2023 Jun 1;30(7):e230044. doi: 10.1530/ERC-23-0044. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37079309
Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients.
Tatarano S, Mitsuke A, Sakaguchi T, Matsushita R, Inoguchi S, Yoshino H, Nishimura H, Yamada Y, Enokida H. Tatarano S, et al. Int J Nephrol. 2022 Jul 21;2022:3060647. doi: 10.1155/2022/3060647. eCollection 2022. Int J Nephrol. 2022. PMID: 35910424 Free PMC article.
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Shiota M, et al. Among authors: tatarano s. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213 Free PMC article.
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators. Blas L, et al. Among authors: tatarano s. Int J Urol. 2023 Sep;30(9):788-796. doi: 10.1111/iju.15265. Epub 2023 Aug 1. Int J Urol. 2023. PMID: 37528632
Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma.
Kawakami I, Yoshino H, Fukumoto W, Tamai M, Okamura S, Osako Y, Sakaguchi T, Inoguchi S, Matsushita R, Yamada Y, Tatarano S, Nakagawa M, Enokida H. Kawakami I, et al. Among authors: tatarano s. Biochem Biophys Res Commun. 2022 Jun 30;611:99-106. doi: 10.1016/j.bbrc.2022.04.068. Epub 2022 Apr 20. Biochem Biophys Res Commun. 2022. PMID: 35487063 Free article.
Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma.
Yoshino H, Tatarano S, Tamai M, Tsuruda M, Iizasa S, Arima J, Kawakami I, Fukumoto W, Kawahara I, Li G, Sakaguchi T, Inoguchi S, Yamada Y, Enokida H. Yoshino H, et al. Among authors: tatarano s. Biochem Biophys Res Commun. 2022 Nov 19;630:71-76. doi: 10.1016/j.bbrc.2022.09.056. Epub 2022 Sep 16. Biochem Biophys Res Commun. 2022. PMID: 36150242 Free article.
Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
Yoshino H, Yokoyama S, Tamai M, Okamura S, Iizasa S, Sakaguchi T, Osako Y, Inoguchi S, Matsushita R, Yamada Y, Nakagawa M, Tatarano S, Tanimoto A, Enokida H. Yoshino H, et al. Among authors: tatarano s. FEBS Open Bio. 2023 Jun;13(6):1056-1066. doi: 10.1002/2211-5463.13616. Epub 2023 Apr 29. FEBS Open Bio. 2023. PMID: 37079001 Free PMC article.
Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer.
Sugita S, Yoshino H, Yonemori M, Miyamoto K, Matsushita R, Sakaguchi T, Itesako T, Tatarano S, Nakagawa M, Enokida H. Sugita S, et al. Among authors: tatarano s. Int J Oncol. 2019 Jun;54(6):2222-2236. doi: 10.3892/ijo.2019.4762. Epub 2019 Mar 22. Int J Oncol. 2019. PMID: 30942440
Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.
Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T. Kita Y, et al. Among authors: tatarano s. Urol Oncol. 2022 Sep;40(9):410.e11-410.e18. doi: 10.1016/j.urolonc.2022.04.005. Epub 2022 May 9. Urol Oncol. 2022. PMID: 35551861
57 results